Related Experiment Video
Updated: Aug 18, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
In vitro and in vivo studies on the anticancer activity of dehydroilludin M
M J Kelner1, T C McMorris, R Taetle
1Department of Pathology 8320, University of California, Medical Center, San Diego 92103, USA.
Abstract:
Six first-generation illudin analogs were tested for antitumor activity using in vitro cytotoxicity and in vivo xenograft models. One analog, dehydroilludin M, inhibited xenograft growth and prolonged life span of tumor bearing animals, when administered IP or IV, whereas the parent Illudin S compound was ineffective. The efficacy of dehydroilludin M in the MV522 lung carcinoma model exceeded that of 9 known anticancer drugs, and equaled that of mitomycin C. Dehydroilludin M retained the in vitro relative selective cytotoxicity for carcinomas and myeloid leukemia cell lines noted with the parent illudin compounds. In vitro cytotoxicity data predicted response of xenografts. Dehydroilludin M also retained the in vitro activity of the parent compounds against different multidrug resistant mdr cell lines.
Insights
Dehydroilludin M, a novel illudin analog, demonstrated significant antitumor activity against xenografts, outperforming existing drugs. This compound shows promise for cancer treatment, retaining efficacy against multidrug-resistant cell lines.
Area of Science:
- Natural Products Chemistry
- Pharmacology
- Oncology
Background:
- Illudins are natural products with known cytotoxic properties.
- The parent compound, Illudin S, showed limited therapeutic potential in preclinical models.
- Development of novel illudin analogs is crucial for exploring new anticancer agents.
Purpose of the Study:
- To evaluate the antitumor activity of six first-generation illudin analogs.
- To compare the efficacy of dehydroilludin M with established anticancer drugs.
- To assess the activity of dehydroilludin M against multidrug-resistant cancer cell lines.
Main Methods:
- In vitro cytotoxicity assays using various cancer cell lines.
- In vivo xenograft models to assess antitumor efficacy.
- Administration of compounds via intraperitoneal (IP) or intravenous (IV) routes.
Main Results:
- Dehydroilludin M significantly inhibited xenograft growth and prolonged survival in tumor-bearing animals.
- The efficacy of dehydroilludin M in the MV522 lung carcinoma model was superior to nine anticancer drugs and comparable to mitomycin C.
- Dehydroilludin M maintained selective cytotoxicity against carcinoma and myeloid leukemia cell lines.
- In vitro cytotoxicity predicted in vivo xenograft response.
- Dehydroilludin M retained activity against multidrug-resistant cell lines.
Conclusions:
- Dehydroilludin M is a potent anticancer agent with promising therapeutic potential.
- Its efficacy against multidrug-resistant cancers warrants further investigation.
- In vitro data can effectively predict in vivo responses for illudin analogs.
More Related Videos
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
13:17In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
